Biological aspects in controlling angiogenesis: current progress.

All living beings continue their life by receiving energy and by excreting waste products. In animals, the arteries are the pathways of these transfers to the cells. Angiogenesis, the formation of the arteries by the development of pre-existed parental blood vessels, is a phenomenon that occurs naturally during puberty due to certain physiological processes such as menstruation, wound healing, or the adaptation of athletes’ bodies during exercise. Nonetheless, the same life-giving process also occurs frequently in some patients and, conversely, occurs slowly in some physiological problems, such as cancer and diabetes, so inhibiting angiogenesis has been considered to be one of the important strategies to fight these diseases. Accordingly, in tissue engineering and regenerative medicine, the highly controlled process of angiogenesis is very important in tissue repairing. Excessive angiogenesis can promote tumor progression and lack of enough angiogensis can hinder tissue repair. Thereby, both excessive and deficient angiogenesis can be problematic, this review article introduces and describes the types of factors involved in controlling angiogenesis. Considering all of the existing strategies, we will try to lay out the latest knowledge that deals with stimulating/inhibiting the angiogenesis. At the end of the article, owing to the early-reviewed mechanical aspects that overshadow angiogenesis, the strategies of angiogenesis in tissue engineering will be discussed. Similar content being viewed by others Availability of data and materials All data generated or analyzed during this study are included in this published article.

Folkman J (2006) Angiogenesis. J Annu Rev Med 57:1–18 Senger DR, Davis GE (2011) Angiogenesis. Cold Spring Harb Perspect Biol 3(8):a005090 Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186 Conway EM, Collen D, Carmeliet P (2001) Molecular mechanisms of blood vessel growth. Cardiovasc Res 49(3):507–521 Ucuzian AA et al (2010) Molecular mediators of angiogenesis. J Burn Care 31(1):158–175 Nyberg P, Xie L, Kalluri R (2005) Endogenous inhibitors of angiogenesis. Can Res 65(10):3967–3979 Martínez A (2006) A new family of angiogenic factors. Cancer Lett 236(2):157–163 Ribatti D, Crivellato E (2012) “Sprouting angiogenesis”, a reappraisal. Dev Biol 372(2):157–165 Cai W, Schaper W (2008) Mechanisms of arteriogenesis. Acta Biochim Biophys Sin 40(8):681–692 Krock BL et al (2011) Hypoxia-induced angiogenesis: good and evil. Genes 2(12):1117–1133 Olsson A-K et al (2006) VEGF receptor signalling? In control of vascular function. Nat Rev Mol Cell Biol 7(5):359–371 Stepien HM et al (2002) Angiogenesis of endocrine gland tumours-new molecular targets in diagnostics and therapy. Eur J Endocrinol 146(2):143–152 Trikha M et al (2002) Multiple roles for platelet GPIIb/IIIa and αvβ3 integrins in tumor growth, angiogenesis, and metastasis. Can Res 62(10):2824–2833 Salvucci O, Tosato G (2012) Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis. Adv Cancer Res 114:21–57 Folkman J (2006) Angiogenesis. Annu Rev Med 57:1–18 Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347):298–307 Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039–2049 Shikatani EA et al (2012) Inhibition of proliferation, migration and proteolysis contribute to corticosterone-mediated inhibition of angiogenesis. PLoS One 7:e46625 Pasquet M et al (2010) Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. Int J Cancer 126(9):2090–2101 Dudley AC, Cloer EW, Melero-Martin JM (2012) The role of bone marrow-derived progenitor cells in tumor growth and angiogenesis. Stem cells and cancer stem cells, vol 8. Springer, pp 45–54 Sica A et al (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42(6):717–727 Harrell CR et al (2018) Molecular mechanisms underlying therapeutic potential of pericytes. J Biomed Sci 25(1):1–12 Tilton RG, Kilo C, Williamson JR (1979) Pericyte-endothelial relationships in cardiac and skeletal muscle capillaries. Microvasc Res 18(3):325–335 Shepro D, Morel NM (1993) Pericyte physiology. FASEB J 7(11):1031–1038 Gaengel K et al (2009) Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 29(5):630–638 Lee S et al (2010) Pericyte actomyosin-mediated contraction at the cell–material interface can modulate the microvascular niche. J Phys Condens Matter 22(19):194115 Chen CW et al (2013) Human pericytes for ischemic heart repair. Stem Cells 31(2):305–316 Proebstl D et al (2012) Pericytes support neutrophil subendothelial cell crawling and breaching of venular walls in vivo. J Exp Med 209(6):1219–1234 Zanotelli MR, Reinhart-King CA (2018) Mechanical forces in tumor angiogenesis. Adv Exp Med Biol 1092:91–112. https://doi.org/10.1007/978-3-319-95294-9_6 Underwood CJ et al (2014) Cell-generated traction forces and the resulting matrix deformation modulate microvascular alignment and growth during angiogenesis. Am J Physiol Heart Circ Physiol 307(2):H152–H164 Chicurel ME, Chen CS, Ingber DE (1998) Cellular control lies in the balance of forces. Curr Opin Cell Biol 10(2):232–239 Galbraith CG, Sheetz MP (1998) Forces on adhesive contacts affect cell function. Curr Opin Cell Biol 10(5):566–571 Sieminski A, Hebbel R, Gooch K (2004) The relative magnitudes of endothelial force generation and matrix stiffness modulate capillary morphogenesis in vitro. Exp Cell Res 297(2):574–584 Kuzuya M et al (1996) Inhibition of endothelial cell differentiation on a glycosylated reconstituted basement membrane complex. Exp Cell Res 226(2):336–345 Deroanne CF, Lapiere CM, Nusgens BV (2001) In vitro tubulogenesis of endothelial cells by relaxation of the coupling extracellular matrix-cytoskeleton. Cardiovasc Res 49(3):647–658 Vernon RB et al (1995) Organized type I collagen influences endothelial patterns during “spontaneous angiogenesis in vitro”: planar cultures as models of vascular development. In Vitro Cell Dev Biol Anim 31(2):120–131 Ausprunk DH, Folkman J (1977) Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14(1):53–65 Shiu Y-T et al (2005) The role of mechanical stresses in angiogenesis. Crit Rev Biomed Eng 33(5):431–510 Vernon RB et al (1992) Reorganization of basement membrane matrices by cellular traction promotes the formation of cellular networks in vitro. Lab Investig 66(5):536–547 Vernon RB, Sage EH (1995) Between molecules and morphology. Extracellular matrix and creation of vascular form. Am J Pathol 147(4):873 Davies PF (1995) Flow-mediated endothelial mechanotransduction. Physiol Rev 75(3):519–560 Krishnan L et al (2003) Effects of angiogenesis on the material properties of the extracellular matrix: correlation with gene expression. In: Proceedings of the ASME summer bioengineering conference Clark ER (1918) Studies on the growth of blood-vessels in the tail of the frog larva—by observation and experiment on the living animal. Am J Anat 23(1):37–88 Rivilis I et al (2002) Differential involvement of MMP-2 and VEGF during muscle stretch-versus shear stress-induced angiogenesis. Am J Physiol Heart Circ Physiol 283(4):H1430–H1438 Van Gieson EJ, Skalak TC (2001) Chronic vasodilation induces matrix metalloproteinase 9 (MMP-9) expression during microvascular remodeling in rat skeletal muscle. Microcirculation 8(1):25–31 Egginton S et al (2001) Unorthodox angiogenesis in skeletal muscle. Cardiovasc Res 49(3):634–646 Egginton S et al (1998) Capillary growth in relation to blood flow and performance in overloaded rat skeletal muscle. J Appl Physiol 85(6):2025–2032 Bamias A, Dimopoulos MA (2003) Angiogenesis in human cancer: implications in cancer therapy. Eur J Intern Med 14(8):459–469 Gupta MK, Qin R-Y (2003) Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol WJG 9(6):1144 Hertig AT (1935) Angiogenesis in the early human chorion and in the primary placenta of the macaque monkey. Control Embryol 146:37–82 Martin P (1997) Wound healing–aiming for perfect skin regeneration. Science 276(5309):75–81 Clark RA (1988) Wound repair. The molecular and cellular biology of wound repair. Springer, New York, pp 3–50 Albert S (2002) Cost-effective management of recalcitrant diabetic foot ulcers. Clin Podiatr Med 19(4):483–491 Kanitakis J (2002) Anatomy, histology and immunohistochemistry of normal human skin. Eur J Dermatol 12(4):390–401 Clark RA (1993) Regulation of fibroplasia in cutaneous wound repair. Am J Med Sci 306(1):42–48 McNeil PL, Kirchhausen T (2005) An emergency response team for membrane repair. Nat Rev Mol Cell Biol 6(6):499–505 Roy S et al (2008) Characterization of the acute temporal changes in excisional murine cutaneous wound inflammation by screening of the wound-edge transcriptome. Physiol Genom 34(2):162–184 Cheng C-F et al (2008) Profiling motility signal-specific genes in primary human keratinocytes. J Investig Dermatol 128(8):1981–1990 Ito M et al (2007) Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding. Nature 447(7142):316–320 Becker CM, D’Amato RJ (2007) Angiogenesis and antiangiogenic therapy in endometriosis. Microvasc Res 74(2–3):121–130 May K, Becker C (2008) Endometriosis and angiogenesis. Minerva Ginecol 60(3):245–254 Sourial S, Tempest N, Hapangama DK (2014) Theories on the pathogenesis of endometriosis. Int J Reprod Med 2014:1–9 Witz CA (2002) Pathogenesis of endometriosis. Gynecol Obstet Investig 53(Suppl. 1):52–62 McLaren J et al (1996) Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 11(1):220–223 Mueller MD et al (2000) Neutrophils infiltrating the endometrium express vascular endothelial growth factor: potential role in endometrial angiogenesis. Fertil Steril 74(1):107–112 Hyder SM et al (2000) Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60(12):3183–3190 Hull ML et al (2003) Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab 88(6):2889–2899 Folkman J (1974) Tumor angiogenesis factor. Can Res 34(8):2109–2113 Kerbel RS (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312(5777):1171–1175 Al-Husein B et al (2012) Antiangiogenic therapy for cancer: an update. Pharmacother J Hum Pharmacol Drug Ther 32(12):1095–1111 Gupta K, Zhang J (2005) Angiogenesis: a curse or cure? Postgrad Med J 81(954):236–242 Cines DB et al (1998) Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood J Am Soc Hematol 91(10):3527–3561 Sennino B et al (2007) Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Can Res 67(15):7358–7367 Griffioen AW, Molema G (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52(2):237–268 Murohara T et al (1998) Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Investig 101(11):2567–2578 Pandya NM, Dhalla NS, Santani DD (2006) Angiogenesis—a new target for future therapy. Vasc Pharmacol 44(5):265–274 Furuya M, Yonemitsu Y (2008) Cancer neovascularization and proinflammatory microenvironments. Curr Cancer Drug Targets 8(4):253–265 Furuya M et al (2005) Pathophysiology of tumor neovascularization. Vasc Health Risk Manag Healthc Policy 1(4):277 Ribatti D et al (2007) The structure of the vascular network of tumors. Cancer Lett 248(1):18–23 Croix BS et al (2000) Genes expressed in human tumor endothelium. Science 289(5482):1197–1202 Parker BS et al (2004) Alterations in vascular gene expression in invasive breast carcinoma. Can Res 64(21):7857–7866 Madden SL et al (2004) Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 165(2):601–608 Dvorak H (2005) Angiogenesis: update 2005. J Thromb Haemost 3(8):1835–1842 Rajabi M, Mousa SA (2017) The role of angiogenesis in cancer treatment. Biomedicines 5(2):34 Hirakawa S et al (2005) VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201(7):1089–1099 Nishida N et al (2006) Angiogenesis in cancer. Vasc Health Risk Manag Healthc Policy 2(3):213 Marneros AG (2009) Tumor angiogenesis in melanoma. Hematol Oncol Clin 23(3):431–446 Martin MJ et al (2012) Metformin accelerates the growth of BRAFV600E-driven melanoma by upregulating VEGF-A. Cancer Discov 2(4):344–355 Stec M et al (2015) Isolation and characterization of circulating micro (nano) vesicles in the plasma of colorectal cancer patients and their interactions with tumor cells. Oncol Rep 34(5):2768–2775 Olejarz W, Łacheta D, Kubiak-Tomaszewska G (2020) Matrix metalloproteinases as biomarkers of atherosclerotic plaque instability. Int J Mol Sci 21(11):3946 Skog J et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10(12):1470–1476 Kanninen KM et al (2016) Exosomes as new diagnostic tools in CNS diseases. Biochim Biophys Acta Mol Basis Dis 1862(3):403–410 Esa A et al (2019) Extracellular vesicles in the synovial joint: is there a role in the pathophysiology of osteoarthritis? Malays Orthop J 13(1):1 Zeng Y et al (2019) Anti-angiogenesis triggers exosomes release from endothelial cells to promote tumor vasculogenesis. J Extracell Vesicles 8(1):1629865 Whiteside TL (2016) Tumor-derived exosomes and their role in cancer progression. Adv Clin Chem 74:103–141 Huang A et al (2015) Exosomal transfer of vasorin expressed in hepatocellular carcinoma cells promotes migration of human umbilical vein endothelial cells. Int J Biol Sci 11(8):961 Qu L et al (2016) Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell 29(5):653–668 Yeo RWY et al (2013) Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev 65(3):336–341 Chen B et al (2019) Human embryonic stem cell-derived exosomes promote pressure ulcer healing in aged mice by rejuvenating senescent endothelial cells. Stem Cell Res 10(1):1–17 Waltenberger J (2007) New horizons in diabetes therapy: the angiogenesis paradox in diabetes: description of the problem and presentation of a unifying hypothesis. Immunol Endocr Metab Agents Med Chem 7(1):87–93 Martin A, Komada MR, Sane DC (2003) Abnormal angiogenesis in diabetes mellitus. Med Res Rev 23(2):117–145 Cheng R, Ma J-X (2015) Angiogenesis in diabetes and obesity. Rev Endocr Metab Disord 16(1):67–75 Okonkwo UA, DiPietro LA (2017) Diabetes and wound angiogenesis. Int J Mol Sci 18(7):1419 Tomanek RJ, Schatteman GC (2000) Angiogenesis: new insights and therapeutic potential. Anat Rec 261(3):126–135 Abacı A et al (1999) Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99(17):2239–2242 Werner GS et al (2001) Collateral function in chronic total coronary occlusions is related to regional myocardial function and duration of occlusion. Circulation 104(23):2784–2790 Tan S et al (2021) Differences of angiogenesis factors in tumor and diabetes mellitus. Diabetes Metab Syndr Obes Targets Ther 14:3375 Kolluru GK, Bir SC, Kevil CG (2012) Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med 2012:1–30 Chung AS, Ferrara N (2011) Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol (New York, N.Y.: 1985) 27:563–584 Humar R, Zimmerli L, Battegay E (2009) Angiogenesis and hypertension: an update. J Hum Hypertens 23(12):773–782 Ferroni P et al (2012) Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies. Curr Vasc Pharmacol 10(4):479–493 Yang JC et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427–434 Felmeden DC et al (2003) Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 16(1):11–20 Sane DC, Anton L, Brosnihan KB (2004) Angiogenic growth factors and hypertension. Angiogenesis 7(3):193–201 Yang R et al (2002) Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension 39(3):815–820 Vila V et al (2008) Inflammation, endothelial dysfunction and angiogenesis markers in chronic heart failure patients. Int J Cardiol 130(2):276–277 Kiefer FN et al (2004) A versatile in vitro assay for investigating angiogenesis of the heart. Exp Cell Res 300(2):272–282 Grass TM, Lurie DI, Coffin JD (2006) Transitional angiogenesis and vascular remodeling during coronary angiogenesis in response to myocardial infarction. Acta Histochem 108(4):293–302 Rouwkema J, Rivron NC, van Blitterswijk CA (2008) Vascularization in tissue engineering. Trends Biotechnol 26(8):434–441 Adams RH, Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8(6):464–478 Kaully T et al (2009) Vascularization—the conduit to viable engineered tissues. Tissue Eng Part B Rev 15(2):159–169 Birla R (2014) Introduction to tissue engineering: applications and challenges. Wiley, Hoboken Atluri P, Woo YJ (2008) Pro-angiogenic cytokines as cardiovascular therapeutics. BioDrugs 22(4):209–222 Wang Y et al (2018) New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications. Mol Cancer 17(1):1–10 Ferrara N, Gerber H-P, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669–676 Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl. 3):4–10 George ML et al (2001) Vegf-a, vegf-c, and vegf-d in colorectal cancer progression. Neoplasia 3(5):420–427 Struman I et al (1999) Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci 96(4):1246–1251 Hoeben A et al (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56(4):549–580 Rissanen TT et al (2003) VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 92(10):1098–1106 Zhao H-C et al (2006) Microvessel density is a prognostic marker of human gastric cancer. World J Gastroenterol WJG 12(47):7598 Huwer H et al (2001) Simultaneous surgical revascularization and angiogenic gene therapy in diffuse coronary artery disease. Eur J Cardiothorac Surg 20(6):1128–1134 Celik T et al (2005) Impaired coronary collateral vessel development in patients with proliferative diabetic retinopathy. Clin Cardiol Int Index Peer Rev J Adv Treat Cardiovasc Dis 28(8):384–388 Chou E et al (2002) Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 105(3):373–379 Aiello LP, Wong J-S (2000) Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int 58:S113–S119 Chen S, Ziyadeh FN (2008) Vascular endothelial growth factor and diabetic nephropathy. Curr Diabetes Rep 8(6):470–476 Raab S, Plate KH (2007) Different networks, common growth factors: shared growth factors and receptors of the vascular and the nervous system. Acta Neuropathol 113(6):607–626 Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9(6):653–660 Hall H (2007) Modified fibrin hydrogel matrices: both, 3D-scaffolds and local and controlled release systems to stimulate angiogenesis. Curr Pharm Des 13(35):3597–3607 Peng S et al (2021) LncRNA-AK137033 inhibits the osteogenic potential of adipose-derived stem cells in diabetic osteoporosis by regulating Wnt signaling pathway via DNA methylation. Cell Prolif 55:e13174 Son J et al (2019) DNA aptamer immobilized hydroxyapatite for enhancing angiogenesis and bone regeneration. Acta Biomater 99:469–478 Hardy B et al (2007) Angiogenesis induced by novel peptides selected from a phage display library by screening human vascular endothelial cells under different physiological conditions. Peptides 28(3):691–701 Cavanagh PR et al (2005) Treatment for diabetic foot ulcers. Lancet 366(9498):1725–1735 Van Hove AH, Benoit DS (2015) Depot-based delivery systems for pro-angiogenic peptides: a review. Front Bioeng Biotechnol Adv 3:102 Pickart L (2008) The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 19(8):969–988 Akeson AL et al (1996) AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1. J Biol Chem 271(48):30517–30523 Mandrup-Poulsen T (2012) Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes. Rev Diabet Stud RDS 9(4):338 Olsson A-K et al (2004) The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Can Res 64(24):9012–9017 Chew CK, Clarke BL (2017) Abaloparatide: recombinant human PTHrP (1–34) anabolic therapy for osteoporosis. Maturitas 97:53–60 Zhanel GG, Schweizer F, Karlowsky JA (2012) Oritavancin: mechanism of action. Clin Infect Dis 54(suppl_3):S214–S219 Finetti F et al (2012) Functional and pharmacological characterization of a VEGF mimetic peptide on reparative angiogenesis. Biochem Pharmacol 84(3):303–311 Slyke P, Dumont D (2011) Multimeric TIE 2 agonists and uses thereof in stimulating angiogenesis. USA Patent Application. Demidova-Rice TN, Geevarghese A, Herman IM (2011) Bioactive peptides derived from vascular endothelial cell extracellular matrices promote microvascular morphogenesis and wound healing in vitro. Wound Repair Regen 19(1):59–70 Demidova-Rice TN et al (2012) Human platelet-rich plasma-and extracellular matrix-derived peptides promote impaired cutaneous wound healing in vivo. PLoS One 7(2):e32146 Licht T et al (2003) Induction of pro-angiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P3 (EDG3). Blood 102(6):2099–2107 Soro S et al (2008) A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through α5β1 integrin. Blood J Am Soc Hematol 111(7):3479–3488 Liu J-M et al (2003) The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo. Blood J Am Soc Hematol 101(8):3014–3020 Gao N et al (2002) Vanadate-induced expression of hypoxia-inducible factor 1α and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J Biol Chem 277(35):31963–31971 Nishio S et al (2008) Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma. Cancer Lett 264(1):36–43 Chua M-S et al (2007) Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Mod Pathol 20(1):76–83 Mousa SA et al (2007) Pro-angiogenesis action of arsenic and its reversal by selenium-derived compounds. Carcinogenesis 28(5):962–967 Raines AL et al (2010) Regulation of angiogenesis during osseointegration by titanium surface microstructure and energy. Biomaterials 31(18):4909–4917 Zhai W et al (2012) Silicate bioceramics induce angiogenesis during bone regeneration. Acta Biomater 8(1):341–349 Li H, Chang J (2013) Bioactive silicate materials stimulate angiogenesis in fibroblast and endothelial cell co-culture system through paracrine effect. Acta Biomater 9(6):6981–6991 Das S et al (2012) The induction of angiogenesis by cerium oxide nanoparticles through the modulation of oxygen in intracellular environments. Biomaterials 33(31):7746–7755 Chachami G et al (2004) Cobalt induces hypoxia-inducible factor-1α expression in airway smooth muscle cells by a reactive oxygen species—and PI3K-dependent mechanism. Am J Respir Cell Mol Biol Evol 31(5):544–551 Bracken C, Whitelaw M, Peet D (2003) The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses. Cell Mol Life Sci 60(7):1376–1393 Bollu VS et al (2016) Evaluation of in vivo cytogenetic toxicity of europium hydroxide nanorods (EHNs) in male and female Swiss albino mice. ACS Biomater Sci 10(4):413–425 Ge K et al (2016) Europium-doped NaYF 4 nanoparticles cause the necrosis of primary mouse bone marrow stromal cells through lysosome damage. RSC Adv 6(26):21725–21734 Papapetropoulos A et al (2009) Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci 106(51):21972–21977 Coletta C et al (2012) Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc Natl Acad Sci 109(23):9161–9166 Mao CD, Hoang P, DiCorleto PE (2001) Lithium inhibits cell cycle progression and induces stabilization of p53 in bovine aortic endothelial cells. J Biol Chem 276(28):26180–26188 Nethi SK et al (2017) Pro-angiogenic properties of terbium hydroxide nanorods: molecular mechanisms and therapeutic applications in wound healing. ACS Biomater Sci Eng Min J 3(12):3635–3645 Augustine R et al (2019) Yttrium oxide nanoparticle loaded scaffolds with enhanced cell adhesion and vascularization for tissue engineering applications. Mater Sci Eng C 103:109801 Boehm T et al (1998) Zinc-binding of endostatin is essential for its antiangiogenic activity. Biochem Biophys Res Commun 252(1):190–194 Ding Y-H et al (1998) Zinc-dependent dimers observed in crystals of human endostatin. Proc Natl Acad Sci 95(18):10443–10448 Loboda A et al (2008) Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 10(10):1767–1812 Gullino P (1986) Considerations on the mechanism of the angiogenic response. Anticancer Res 6(2):153–158 Raju KS et al (1982) Ceruloplasmin, copper ions, and angiogenesis. J Natl Cancer Inst 69(5):1183–1188 Kohn EC et al (1995) Angiogenesis: role of calcium-mediated signal transduction. Proc Natl Acad Sci 92(5):1307–1311 Dzondo-Gadet M et al (2002) Action of boron at the molecular level. Biol Trace Elem Res 85(1):23–33 Bernardini D et al (2005) Magnesium and microvascular endothelial cells: a role in inflammation and angiogenesis. Front Biosci 10(1–3):1177–1182 Miguez-Pacheco V et al (2018) Development and characterization of niobium-releasing silicate bioactive glasses for tissue engineering applications. J Eur Ceram Soc 38(3):871–876 Malhotra A, Habibovic P (2016) Calcium phosphates and angiogenesis: implications and advances for bone regeneration. Trends Biotechnol 34(12):983–992 Liang H-C et al (2005) Loading of a novel angiogenic agent, ginsenoside Rg1 in an acellular biological tissue for tissue regeneration. Tissue Eng 11(5–6):835–846 Yue PY et al (2005) Elucidation of the mechanisms underlying the angiogenic effects of ginsenoside Rg 1 in vivo and in vitro. Angiogenesis 8(3):205–216 Sengupta S et al (2004) Modulating angiogenesis: the yin and the yang in ginseng. Circulation 110(10):1219–1225 Hong SJ et al (2009) Angiogenic effect of saponin extract from Panax notoginseng on HUVECs in vitro and zebrafish in vivo. Phytother Res Int J Devot Pharmacol Toxicol Eval Nat Prod Deriv 23(5):677–686 Huang Y-C et al (2005) A natural compound (ginsenoside Re) isolated from Panax ginseng as a novel angiogenic agent for tissue regeneration. Pharm Res 22(4):636–646 Xin X et al (2006) Extraction of 20 (S)-ginsenoside Rg2 from cultured Panax notoginseng cells in vitro stimulates human umbilical cord vein endothelial cell proliferation. Am J Ther 13(3):205–210 Choi S et al (2002) Angiogenic activity of β-sitosterol in the ischaemia/reperfusion-damaged brain of Mongolian gerbil. Planta Med 68(04):330–335 Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77(7):527–543 Meng H et al (2008) Angiogenic effects of the extracts from Chinese herbs: Angelica and Chuanxiong. Am J Chin Med 36(03):541–554 Lam HW et al (2008) The angiogenic effects of Angelica sinensis extract on HUVEC in vitro and zebrafish in vivo. J Cell Biochem 103(1):195–211 Zhang Y et al (2009) Radix Astragali extract promotes angiogenesis involving vascular endothelial growth factor receptor-related phosphatidylinositol 3-kinase/Akt-dependent pathway in human endothelial cells. Phytother Res Int J Devot Pharmacol Toxicol Eval Nat Prod Deriv 23(9):1205–1213 Zheng KY et al (2011) Flavonoids from Radix Astragali induce the expression of erythropoietin in cultured cells: a signaling mediated via the accumulation of hypoxia-inducible factor-1α. J Agric Food Chem 59(5):1697–1704 Choi D-Y et al (2009) Stimulatory effect of Cinnamomum cassia and cinnamic acid on angiogenesis through up-regulation of VEGF and Flk-1/KDR expression. Int Immunopharmacol 9(7–8):959–967 Chen H et al (2012) Reconstitution of coronary vasculature in ischemic hearts by plant-derived angiogenic compounds. Int J Cardiol 156(2):148–155 Zhang Q et al (2021) Tetrahedral framework nucleic acids act as antioxidants in acute kidney injury treatment. Chem Eng J 413:127426 Zhang T et al (2020) Design, fabrication and applications of tetrahedral DNA nanostructure-based multifunctional complexes in drug delivery and biomedical treatment. Nat Protoc 15(8):2728–2757 Liu Y et al (2020) Tetrahedral framework nucleic acids deliver antimicrobial peptides with improved effects and less susceptibility to bacterial degradation. Nano Lett 20(5):3602–3610 Yoshitomi T et al (2020) Binding and structural properties of DNA aptamers with VEGF-A-mimic activity. Mol Ther Nucleic Acids 19:1145–1152 Nonaka Y et al (2013) Affinity improvement of a VEGF aptamer by in silico maturation for a sensitive VEGF-detection system. Anal Chem 85(2):1132–1137 Zhao D et al (2020) Tetrahedral framework nucleic acid promotes the treatment of bisphosphonate-related osteonecrosis of the jaws by promoting angiogenesis and M2 polarization. ACS Appl Mater Interfaces 12(40):44508–44522 Lin S et al (2020) Antioxidative and angiogenesis-promoting effects of tetrahedral framework nucleic acids in diabetic wound healing with activation of the Akt/Nrf2/HO-1 pathway. ACS Appl Mater Interfaces 12(10):11397–11408 Juhl O IV et al (2019) Aptamer-functionalized fibrin hydrogel improves vascular endothelial growth factor release kinetics and enhances angiogenesis and osteogenesis in critically sized cranial defects. ACS Biomater Sci Eng Min J 5(11):6152–6160 Khademhosseini A, Vacanti JP, Langer R (2009) Progress in tissue engineering. Sci Am 300(5):64–71 Song H-HG et al (2018) Vascular tissue engineering: progress, challenges, and clinical promise. Cell Stem Cell 22(3):340–354 Ravi S, Chaikof EL (2010) Biomaterials for vascular tissue engineering. Regen Med 5(1):107–120 Lovett M et al (2009) Vascularization strategies for tissue engineering. Tissue Eng Part B Rev 15(3):353–370 Li S, Sengupta D, Chien S (2014) Vascular tissue engineering: from in vitro to in situ. Wiley Interdiscip Rev Syst Biol Med Glob Surviv 6(1):61–76 Leal BB et al (2021) Vascular tissue engineering: polymers and methodologies for small caliber vascular grafts. Front Cardiovasc Med 7:376 Liu Y, Chan-Park MB (2009) Hydrogel based on interpenetrating polymer networks of dextran and gelatin for vascular tissue engineering. Biomaterials 30(2):196–207 Ma H, Hu J, Ma PX (2010) Polymer scaffolds for small-diameter vascular tissue engineering. Adv Func Mater 20(17):2833–2841 Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108(2):153–164 Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2(10):727–739 Makrilia N et al (2009) The role of angiogenesis in solid tumours: an overview. Eur J Intern Med 20(7):663–671 Gold L et al (2012) Aptamers and the RNA World, Past and Present. Cold Spring Harb Perspect Biol 4:a003582 Ribatti D (2009) Endogenous inhibitors of angiogenesis: a historical review. Leuk Res 33(5):638–644 Kusaka M et al (1991) Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 174(3):1070–1076 Gupta SK, Hassel T, Singh JP (1995) A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci 92(17):7799–7803 Nasir A (2019) Angiogenic signaling pathways and anti-angiogenic therapies in human cancer. Predictive biomarkers in oncology. Springer, New York, pp 243–262 Wu J et al (2020) Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model. Biomed Pharmacother 125:109746 O’Reilly MS et al (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79(2):315–328 Streck CJ et al (2005) Interferon-mediated anti-angiogenic therapy for neuroblastoma. Cancer Lett 228(1–2):163–170 Briukhovetska D et al (2021) Interleukins in cancer: from biology to therapy. Nat Rev Cancer 21:1–19 Lee G-R, Ahn M-R (2020) Inhibition of vascular endothelial growth factor-induced angiogenesis by bee products. Korean Society of Food and Nutrition, 430–431 Goto F et al (1993) Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Investig J Tech Methods 69(5):508–517 Li K, Tay FR, Yiu CKY (2020) The past, present and future perspectives of matrix metalloproteinase inhibitors. Pharmacol Ther Clin Risk Manag 207:107465 Shweiki D et al (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359(6398):843–845 Davis S et al (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87(7):1161–1169 Heljasvaara R et al (2005) Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp Cell Res 307(2):292–304 Ortega N, Werb Z (2002) New functional roles for non-collagenous domains of basement membrane collagens. J Cell Sci 115(22):4201–4214 Cook KM, Figg WD (2010) Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60(4):222–243 Fayette J, Soria J-C, Armand J-P (2005) Use of angiogenesis inhibitors in tumour treatment. Eur J Cancer 41(8):1109–1116 Margolin K et al (2001) Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19(3):851–856 Reichert J et al (2010) Development trends for peptide therapeutics. Peptide Therapeutics Foundation Saladin PM, Zhang BD, Reichert JM (2009) Current trends in the clinical development of peptide therapeutics. IDrugs Investig Drugs J 12(12):779–784 Bhutia SK, Maiti TK (2008) Targeting tumors with peptides from natural sources. Trends Biotechnol 26(4):210–217 Rosca VE et al (2011) Anti-angiogenic peptides for cancer therapeutics. Curr Pharm Biotechnol 12(8):1101–1116 Thevenard J et al (2006) Structural and antitumor properties of the YSNSG cyclopeptide derived from tumstatin. Chem Biol Philos 13(12):1307–1315 Park K et al (2008) Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth. Pharm Res 25(12):2786–2798 Doñate F et al (2008) Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin Cancer Res 14(7):2137–2144 Hariharan S et al (2007) Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 18(8):1400–1407 Reardon DA et al (2007) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. Clin Oncol 26:5610–5617 Giordano RJ et al (2010) From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway. Proc Natl Acad Sci 107(11):5112–5117 Juarez JC et al (2002) Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. Can Res 62(18):5344–5350 Dixelius J et al (2006) Minimal active domain and mechanism of action of the angiogenesis inhibitor histidine-rich glycoprotein. Can Res 66(4):2089–2097 Guo Y et al (2002) An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Can Res 62(16):4678–4684 Mishima K et al (2000) A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci 97(15):8484–8489 Haviv F et al (2005) Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 48(8):2838–2846 Ni S et al (2020) Recent progress in aptamer discoveries and modifications for therapeutic applications. ACS Appl Mater Interfaces 13(8):9500–9519 Li L et al (2021) Nucleic acid aptamers for molecular diagnostics and therapeutics: advances and perspectives. Angew Chem Int Ed 60(5):2221–2231 Liu Y et al (2021) Immobilization strategies for enhancing sensitivity of electrochemical aptamer-based sensors. ACS Appl Mater Interfaces 13(8):9491–9499 McConnell EM, Nguyen J, Li Y (2020) Aptamer-based biosensors for environmental monitoring. Front Chem 8:434 Schmitz FRW et al (2020) An overview and future prospects on aptamers for food safety. Appl Microbiol Biotechnol Adv 104:1–11 Proske D et al (2005) Aptamers—basic research, drug development, and clinical applications. Appl Microbiol Biotechnol Adv 69(4):367–374 Carrasquillo KG et al (2003) Controlled delivery of the anti-VEGF aptamer EYE001 with poly (lactic-co-glycolic) acid microspheres. Investig Ophthalmol Vis Sci 44(1):290–299 Drolet DW et al (2000) Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 17(12):1503–1510 Pietras K et al (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Can Res 62(19):5476–5484 Jaffe GJ et al (2016) A phase 1 study of intravitreous E10030 in combination with ranibizumab in neovascular age-related macular degeneration. Ophthalmology 123(1):78–85 Matsuda Y et al (2019) Anti-angiogenic and anti-scarring dual action of an anti-fibroblast growth factor 2 aptamer in animal models of retinal disease. Mol Ther Nucleic Acids 17:819–828 Lu C et al (2010) Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 9(3):176–182 Tezuka-Kagajo M et al (2020) Development of human CBF1-targeting single-stranded DNA aptamers with antiangiogenic activity in vitro. Nucleic Acid Ther 30(6):365–378 Jellinek D et al (1993) High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proc Natl Acad Sci 90(23):11227–11231 Ruckman J et al (1998) 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165): Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273(32):20556–20567 White RR et al (2003) Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci 100(9):5028–5033 Roy T, James BD, Allen JB (2021) Anti-VEGF-R2 aptamer and RGD peptide synergize in a bifunctional hydrogel for enhanced angiogenic potential. Macromol Biosci 21(2):2000337 Muller YA et al (1998) VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 Å resolution and mutational analysis of the interface. Structure 6(9):1153–1167 Asano M, Yukita A, Suzuki H (1999) Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn J Cancer Res 90(1):93–100 Itatani Y et al (2018) Resistance to anti-angiogenic therapy in cancer—alterations to anti-VEGF pathway. Int J Mol Sci 19(4):1232 McCormack PL, Keam SJ (2008) Bevacizumab. Drugs Soc 68(4):487–506 Muyldermans S (2013) Nanobodies: natural single-domain antibodies. Annu Rev Biochem 82:775–797 Arezumand R et al (2017) Nanobodies as novel agents for targeting angiogenesis in solid cancers. Front Immunol 8:1746 Woods J et al (2008) Direct antiangiogenic actions of cadmium on human vascular endothelial cells. Toxicol In Vitro 22(3):643–651 Prozialeck W, Edwards JR, Woods JM (2006) The vascular endothelium as a target of cadmium toxicity. Life Sci 79:1493–1506 Das S et al (2020) Anti-angiogenic vanadium pentoxide nanoparticles for the treatment of melanoma and their in vivo toxicity study. Nanoscale 12(14):7604–7621 Yang MH et al (2017) Anti-angiogenic effect of arsenic trioxide in lung cancer via inhibition of endothelial cell migration, proliferation and tube formation. Oncol Lett 14(3):3103–3109 Jo DH et al (2014) Anti-angiogenic effect of bare titanium dioxide nanoparticles on pathologic neovascularization without unbearable toxicity. Nanomed Nanotechnol Biol Med Glob Surviv 10(5):e1109–e1117 Jo DH et al (2012) Antiangiogenic effect of silicate nanoparticle on retinal neovascularization induced by vascular endothelial growth factor. Biomaterials 8(5):784–791 Kim JH et al (2011) The inhibition of retinal neovascularization by gold nanoparticles via suppression of VEGFR-2 activation. Biomaterials 32(7):1865–1871 Yong JM et al (2022) ROS-mediated anti-angiogenic activity of cerium oxide nanoparticles in melanoma cells. ACS Biomater Sci Eng Min J 8:512–525 Norrby K, Mattsby-Baltzer I, Innocenti M, Tuneberg S (2001) Orally administered bovine lactoferrin systemically inhibits VEGF-mediated angiogenesis in the rat. Int J Cancer 91:236–240 Bussolati B et al (2009) Anti-angiogenic properties of calcium trifluoroacetate. Microvasc Res 78(3):272–277 Maier JA et al (2004) High concentrations of magnesium modulate vascular endothelial cell behaviour in vitro. Biochim Biophys Acta Mol Basis Dis 1689(1):6–12 Ichikawa H et al (2007) Anticancer drugs designed by mother nature: ancient drugs but modern targets. Curr Pharm Des 13(33):3400–3416 Kruger EA et al (2001) Approaches to preclinical screening of antiangiogenic agents. In: Seminars in oncology. Elsevier, Amsterdam Adlercreutz H (1990) Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Investig J Tech Methods 50(sup201):3–23 Donaldson MS (2004) Nutrition and cancer: a review of the evidence for an anti-cancer diet. Nutr J 3(1):1–21 Neal C et al (2006) Clinical aspects of natural anti-angiogenic drugs. Curr Drug Targets 7(3):371–383 Oberlies NH, Kroll DJ (2004) Camptothecin and taxol: historic achievements in natural products research. J Nat Prod 67(2):129–135 Fan T-P et al (2006) Angiogenesis: from plants to blood vessels. Trends Pharmacol Sci 27(6):297–309 Wani MC et al (1971) Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93(9):2325–2327 Kingston D, Newman DJ (2007) Taxoids: cancer-fighting compounds from nature. Curr Opin Drug Discov Dev Change 10(2):130–144 Block G, Patterson B, Subar A (1992) Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 18(1):1–29 Lekas A et al (2005) 147Association of hypoxia inducible factor-1A (HIF-1A), vascular endothelial growth factor (VEGF) and angiogenesis in benign prostate hyperplasia. Eur Urol Suppl 3(4):39 Wall ME et al (1966) Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata1, 2. J Am Chem Soc 88(16):3888–3890 Clements MK et al (1999) Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol Ther 44(5):411–416 Jiang J et al (2019) Combretastatin A4 nanodrug-induced MMP9 amplification boosts tumor-selective release of doxorubicin prodrug. Adv Mater 31(44):1904278 Nainwal LM et al (2019) Combretastatin-based compounds with therapeutic characteristics: a patent review. Expert Opin Ther Pat 29(9):703–731 Seddigi ZS et al (2017) Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents. MedChemComm 8(8):1592–1603 Fotsis T et al (1993) Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci 90(7):2690–2694 Javed Z et al (2021) Genistein as a regulator of signaling pathways and microRNAs in different types of cancers. Cancer Cell Int 21(1):1–12 Guo J et al (2021) Involvement of α7nAChR in the protective effects of genistein against β-amyloid-induced oxidative stress in neurons via a PI3K/Akt/Nrf2 pathway-related mechanism. Cell Mol Neurobiol 41(2):377–393 Kucuk O (2020) Genistein in prostate cancer prevention and treatment. Multidiscip Digit Publ Inst Proc 40(1):49 Sarkar FH, Li YJ (2003) Soy isoflavones and cancer prevention: clinical science review. Cancer Investig 21(5):744–757 Rodriguez SK et al (2006) Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. Int J Cancer Prev 118(7):1635–1644 Lamy S, Gingras D, Béliveau R (2002) Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Can Res 62(2):381–385 Lee B-C et al (2004) The inhibitory effects of aqueous extract of Magnolia officinalis on human mesangial cell proliferation by regulation of platelet-derived growth factor-BB and transforming growth factor-β1 expression. J Pharmacol Sci 94(1):81–85 Lv P et al (2020) Tea polyphenols inhibit the growth and angiogenesis of breast cancer xenografts in a mouse model. J Trad Chin Med Sci 7(2):141–147 Bahramrezaie M et al (2019) Effects of resveratrol on VEGF & HIF1 genes expression in granulosa cells in the angiogenesis pathway and laboratory parameters of polycystic ovary syndrome: a triple-blind randomized clinical trial. J Assist Reprod Genet 36(8):1701–1712 Sudha T et al (2020) Resveratrol and its nanoformulation attenuate growth and the angiogenesis of xenograft and orthotopic colon cancer models. Molecules 25(6):1412 Fukuda S et al (2006) Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem Biophys 44(1):43–49 Zou J et al (2000) Effects of resveratrol on oxidative modification of human low density lipoprotein. Chin Med J 113(2):99–102 Bhat KP, Kosmeder JW, Pezzuto JM (2001) Biological effects of resveratrol. Antioxid Redox Signal 3(6):1041–1064 Guo R et al (2014) Resveratrol suppresses oxidised low-density lipoprotein-induced macrophage apoptosis through inhibition of intracellular reactive oxygen species generation, LOX-1, and the p38 MAPK pathway. Cell Physiol Biochem 34(2):603–616 Petrovski G, Gurusamy N, Das DK (2011) Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci 1215(1):22–33 Liu X et al (2016) The effect and action mechanism of resveratrol on the vascular endothelial cell by high glucose treatment. Saudi J Biol Sci 23(1):S16–S21 Gururaj AE et al (2002) Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun 297(4):934–942 Arbiser JL et al (1998) Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 4(6):376–383 Khafif A et al (2005) Curcumin: a new radio-sensitizer of squamous cell carcinoma cells. Otolaryngol Head Neck Surg 132(2):317–321 Sen S, Sharma H, Singh N (2005) Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem Biophys Res Commun 331(4):1245–1252 Upadhyay N et al (2021) Recent anti-angiogenic drug discovery efforts to combat cancer. ChemistrySelect 6(23):5689–5700 Al-Abd AM et al (2017) Anti-angiogenic agents for the treatment of solid tumors: potential pathways, therapy and current strategies—a review. J Adv Res 8(6):591–605 Cohen DJ, Giordano FJ, Hammond HK, Uham RX, Li W, Pike M, Sellke FW, Stegmann TJ, Udelson JE, Rosengartt TK (2000) Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation 102:E73-86 Chibaudel B et al (2020) Association of bevacizumab plus oxaliplatin-based chemotherapy with disease-free survival and overall survival in patients with stage II colon cancer: a secondary analysis of the AVANT trial. JAMA Netw Open 3(10):e2020425–e2020425 de Castro Junior G et al (2006) Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the “do ut des” paradigm). Crit Rev Oncol Hematol 59(1):40–50 Casparini G et al (2005) Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and other questions. J Clin Oncol 23(6):1295–1311 Horstmann E et al (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352(9):895–904 Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342 Kabbinavar FF et al (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. Eur J Cancer 23(16):3706–3712 D’Hondt V et al (2005) Will the dark sky over advanced renal cell carcinoma soon become brighter? Eur J Cancer 41(9):1246–1253 Escudier B et al (2005) Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 23(16_suppl):4510–4510 Eelen G et al (2020) Basic and therapeutic aspects of angiogenesis updated. Circ Res 127(2):310–329 De Palma M, Biziato D, Petrova TV (2017) Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer 17(8):457–474 Mansoori B et al (2017) The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull 7(3):339 Liu CH et al (2017) Animal models of ocular angiogenesis: from development to pathologies. FASEB J 31(11):4665–4681 Kleinman HK, Martin, GR (2005) Matrigel: basement membrane matrix with biological activity. In: Seminars in cancer biology. Elsevier, Amsterdam

Part of the research reported in this paper was supported by National Institute of Dental & Craniofacial Research of the National Institutes of Health under award numbers R15DE027533, 1 R56DE029191-01A1 and 3R15DE027533-01A1W1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Author information Authors and Affiliations Contributions All authors have contributed equally. Corresponding author Ethics declarations Conflict of interest There are no conflicts to declare. Ethics approval and consent to participate Not applicable. Consent for publication The authors give their consents for the publication of contents of this paper to be published in the Cellular and Molecular Life Sciences. Additional information Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Rights and permissions About this article Cite this article Akbarian, M., Bertassoni, L.E. & Tayebi, L. Biological aspects in controlling angiogenesis: current progress. Cell. Mol. Life Sci. 79, 349 (2022). https://doi.org/10.1007/s00018-022-04348-5 Received: Revised: Accepted: Published: Version of record: DOI: https://doi.org/10.1007/s00018-022-04348-5